About FibroGen
FibroGen is a company based in San Francisco (United States) founded in 1993 by Rory Riggs.. FibroGen has raised $215.5 million across 8 funding rounds from investors including Goldman Sachs, T. Rowe Price and Janus Henderson Investors. The company has 225 employees as of December 31, 2024. FibroGen offers products and services including Roxadustat and FG-3246. FibroGen operates in a competitive market with competitors including Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others.
- Headquarter San Francisco, United States
- Employees 225 as on 31 Dec, 2024
- Founders Rory Riggs
- Stage Public
-
Sectors
Healthcare
-
Phone
*********
-
Website
*********
-
Social
*********
- Legal Name Fibrogen, Inc
-
Annual Revenue
$29.62 M-36.71as on Dec 31, 2024
-
Net Profit
$-47.58 M83.26as on Dec 31, 2024
-
EBITDA
$-128.27 M57.27as on Dec 31, 2024
-
Total Equity Funding
$215.5 M (USD)
in 8 rounds
-
Latest Funding Round
$20 M (USD), Post-IPO
Dec 08, 2014
-
Investors
Goldman Sachs
& 14 more
-
Employee Count
225
as on Dec 31, 2024
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
IPO & Listings of FibroGen
FibroGen is a publicly listed company on the NASDAQ with ticker symbol FGEN in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
Products & Services of FibroGen
FibroGen offers a comprehensive portfolio of products and services, including Roxadustat and FG-3246. The company's diverse product and service offerings are designed to meet the evolving needs of its customers, address market demands, and provide comprehensive solutions that drive value creation and customer satisfaction across various segments and use cases.
Drug for treating anemia associated with chronic kidney disease
Therapy targeting prostate cancer through targeted mechanisms
Unlock access to complete
Leadership Team
13 people
Software Development Team
11 people
Product Management Team
8 people
Legal and Compliance
4 people
Finance and Accounting
4 people
Human Resources and Administration
4 people
Operations Team
3 people
Associate Team
3 people
Unlock access to complete
Funding Insights of FibroGen
FibroGen has successfully raised a total of $215.5M across 8 strategic funding rounds. The most recent funding activity was a Post-IPO round of $20 million completed in December 2014. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding Total Funding
- Total Rounds 8
- Last Round Post-IPO — $20.0M
-
First Round
First Round
(19 Aug 2002)
- Investors Count 15
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec, 2014 | Amount | Post-IPO - FibroGen | Valuation |
investors |
|
| Apr, 2007 | Amount | Series D - FibroGen | Valuation |
investors |
|
| Jan, 2007 | Amount | Series D - FibroGen | Valuation |
investors |
|
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Investors in FibroGen
FibroGen has secured backing from 15 investors, including institutional and venture fund investors. Prominent investors backing the company include Goldman Sachs, T. Rowe Price and Janus Henderson Investors. This diverse investor base provides strategic capital, industry expertise, and valuable network connections that support the company's growth initiatives, market expansion, and long-term value creation.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Multiple sectors are targeted for venture capital investments.
|
Founded Year | Domain | Location | |
|
Biotechnology investments are targeted by the venture capital firm.
|
Founded Year | Domain | Location | |
|
Early-stage life sciences startups are funded by Bio Fund Management.
|
Founded Year | Domain | Location |
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Single family office of Amitabh Bachchan, founder of Amitabh Bachchan Corporation or AB CORP
|
Founded Year | Domain | Location | |
|
Startup ecosystems are ignited through strategic investments by Signite Partners.
|
Founded Year | Domain | Location | |
|
Venture capital is directed toward companies in multiple sectors.
|
Founded Year | Domain | Location | |
|
Venture capital is invested in cybersecurity, fintech, and AI startups.
|
Founded Year | Domain | Location |
Investments & Acquisitions by FibroGen
| Company Name | Description | Domain | Location | Founded Year | Amount |
|---|---|---|---|---|---|
|
Bionic investment advisor platform
|
2016 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 | ||||
|
Physical e-commerce kiosks are deployed for rural purchases in Indonesia.
|
2014 | ||||
|
Fine Asian gourmet food is offered by an internet-first restaurant.
|
2016 |
Financial Statements - FibroGen
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Jan, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
|
| Feb, 2021 | Amount | Post-IPO - Grab | Valuation |
investors |
Fibrogen Comparisons
Competitors of FibroGen
FibroGen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Moderna, BeiGene, Incyte, Ultragenyx and Mereo BioPharma, among others. This competitive environment drives innovation, market differentiation, and strategic positioning as companies strive to capture market share and deliver value to their customers. Understanding the competitive dynamics is crucial for assessing market positioning, identifying growth opportunities, and navigating the challenges inherent in a competitive marketplace.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
mRNA-based therapeutics for diseases including cancer and infections are developed.
|
|
| domain | founded_year | HQ Location |
Targeted and immune-oncology drugs for cancer treatment are developed.
|
|
| domain | founded_year | HQ Location |
Small molecules are developed for cancer and skin disease treatments.
|
|
| domain | founded_year | HQ Location |
Therapeutics for rare and ultra-rare metabolic diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutics for cancer and rare diseases are developed.
|
|
| domain | founded_year | HQ Location |
Therapeutic antibodies for cancer and other diseases are developed.
|
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| domain | founded_year | HQ Location |
Multiple services are booked via an app-based platform.
|
|
| domain | founded_year | HQ Location |
On-demand services are booked through an app-based platform.
|
|
| domain | founded_year | HQ Location |
App based platform offering on demand delivery and ride-hailing services
|
|
| domain | founded_year | HQ Location |
Operates an on-demand hyperlocal delivery app for food and groceries.
|
Latest news on Fibrogen
Frequently Asked Questions about FibroGen
When was FibroGen founded?
FibroGen was founded in 1993 and raised its 1st funding round 9 years after it was founded.
Where is FibroGen located?
FibroGen is headquartered in San Francisco, United States. It is registered at San Francisco, California, United States.
Is FibroGen a funded company?
FibroGen is a funded company, having raised a total of $215.5M across 8 funding rounds to date. The company's 1st funding round was a Series D of $50M, raised on Aug 19, 2002.
How many employees does FibroGen have?
As of Dec 31, 2024, the latest employee count at FibroGen is 225.
What is the annual revenue of FibroGen?
Annual revenue of FibroGen is $29.62M as on Dec 31, 2024.
What does FibroGen do?
FibroGen was founded in 1993 and is headquartered in San Francisco, United States, within the biotechnology sector. Clinical programs in anemia, fibrosis, and oncology have been established through research on connective tissue growth factor (CTGF) and hypoxia-inducible factor (HIF) biology. FG-4592, an oral HIF prolyl hydroxylase inhibitor, is advanced for anemia associated with chronic kidney disease. FG-3019, a monoclonal antibody, targets idiopathic pulmonary fibrosis, pancreatic cancer, and liver fibrosis.
Who are the top competitors of FibroGen?
FibroGen's top competitors include Moderna, BeiGene and Regeneron Pharmaceuticals.
What products or services does FibroGen offer?
FibroGen offers Roxadustat and FG-3246.
Is FibroGen publicly traded?
Yes, FibroGen is publicly traded on NASDAQ under the ticker symbol FGEN.
Who are FibroGen's investors?
FibroGen has 15 investors. Key investors include Goldman Sachs, T. Rowe Price, Janus Henderson Investors, Sigma Capital Group, and Oz Management.
What is FibroGen's ticker symbol?
The ticker symbol of FibroGen is FGEN on NASDAQ.